Comentarios en: Horizon Discovery: audience favorite Global Entrepreneurship Competition

Por: Roberta Rosa

Roberta Rosa — Tue, 16 Jun 2009 11:37:41 +0000

As a young scientist working in the field of target therapy, I can really appreciate the work of Horizon Discovery in developing isogenic cell models applicable to drug discovery for individual patients care. I believe that X-MAN cell lines could be useful to rationalise every aspect of drug discovery pipelines, from the identification of patient-relevant drug targets, to the design of clinical trials based upon the most likely patients to respond to a given drug. Moreover, I greatly appreciate the effort of Horizon Discovery in involving young Italian scientists to grasp the challenge of this international company. For such reason, I sincerely recommend Horizon Discovery as the ideal candidate for this award.

Roberta Rosa, PhD
Laboratory of Molecular Cancer Therapy
University of Naples Federico II, Italy

Por: Sonia Garofalo

Sonia Garofalo — Tue, 16 Jun 2009 09:38:49 +0000

As a research scientist working in Horizon Discovery, I have decided to grasp the challenge of this new company and now I can say I have done the right choice! Horizon Discovery is above all a group of people that believe in their own work: the generation of cell models of complex disease states that can be used to rationalise every aspect of drug discovery pipelines, in order to accelerate the search for new and effective ‘personalised’ medicines. The ‘right drugs’ to the ‘right patients’: a fascinating mission for a motivated team… “we believe”!!!

Por: Dr Michael Murphy

Dr Michael Murphy — Mon, 15 Jun 2009 18:36:07 +0000

As a scientist in a Cambridge start-up company based on an advanced physics technology, I appreciate the world-class science encompassed in this proposition. It has been a very tough 24months even for companies with a large quanta of funding and momentum, so to start a Biotech company in the middle of the UK recession and achieve so much success in 24months is very impressive. This is a testament to the high-quality-science and the ability to close deals.

Por: Shirley Jamieson,

Shirley Jamieson, — Mon, 15 Jun 2009 16:33:41 +0000

Horizon Discovery has a very committed professional senior management team. Also it has a well defined and identifiable marketing strategy. All of the company’s printed material and press releases contain strong clear messages which support the growing business. There is a reason that this company keeps on being recognised by business awards as it is a well run, dynamic company with the combination of a good business model, great technology and an ability for forming good partnerships.

Por: Annarita Zeoli

Annarita Zeoli — Mon, 15 Jun 2009 15:03:40 +0000

Horizon Discovery, in my opinion, represents an amazing venture among the pharmaceutical and biotechnology companies. The goal of this company to generate new drugs that target the unique genetic profile of an individual patient’s cancer is very impressive and stimulating. This new and innovative approach to the cancer treatment underlines an important attention to the patient and to improve his life. I can also appreciate the high quality of scientific background and the important relationship with the academic world that is essential to growth and to become a landmark in the pharmaceutical world. I believe in Horizon Discovery and I support this star-up in the awards!!!!

Por: Sabrina Arena

Sabrina Arena — Mon, 15 Jun 2009 14:05:40 +0000

As a scientist working in the field of cancer genetics applied to target therapy, I can express my positive and enthusiastic appreciation for the great work performed by Horizon Discovery. Isogenic cellular models are a unique precious tool for understanding the role of each target in tumor progression, thus providing new insights for personalized cancer therapy. I strongly support the X-MAN cell-lines technology and I believe that Horizon Discovery will open new avenues to the design of more rational therapies in personalized medicine.

Por: Mariangela Russo

Mariangela Russo — Mon, 15 Jun 2009 13:35:28 +0000

As a PhD student it’s simply exciting to work with Horizon Discovery.

A lot of people more learned than I am have already explained why they believe in Horizon,
it is impressive how fast growing this young start-up is and
how useful the GENESIS technique can be to accelerate the discovery and development of new targeted therapies to enrich the field of the personalised therapy.

Obviously I cannot be considered impartial, but I’d like to let you know another point of view; what is the meaning for me to be involved in this project called Horizon?

When each student starts his research career, he really believes that his 12-13 hours of work per day, seven days per week, can change the cancer therapy, can help patients in their war against the disease. But everyday it become more clear that the “gap” between the results of his work and therapy is really too big and too long.

I really believe that Horizon, it’s technology, it’s goals can change this, it offers a new point of view, it makes the “gap” shorter.

It’s not only a business company,
it’s a project of people which really believe in the possibility to change the therapy
to give to patients a new tool to enrich their possibility of survival, of success,
not in a far future,
but now!

This is the feeling of the work in Horizon, with it’s great and motivated team,
the possibility to make a significant change!

When a student has the possibility to be involved in a project like this…it’s simply lucky!

Por: Dr Adam Collier

Dr Adam Collier — Fri, 12 Jun 2009 08:35:37 +0000

The rapid growth in the number of deals that Horizon has secured over the last two years serves as a clear indication of the significant return-on-investment that biotech-pharma has identified in working with them, especially in a climate when all companies, large and small, have to justify every penny. As a business development director in the industry, I have experience in routinely assisting scientific colleagues in sourcing new targets with a level of validation than can justify the commitment to initiating a new programme. Access to Horizon’s cell lines and impressive drug discovery expertise to further validate the target and the resulting candidate drugs lends further confidence to this investment, and should help to reduce the “industry standard” attrition rates that we all routinely plug into our planning. This is an excellent concept and is clearly being deployed through a well-considered business model.

Por: Derek Jones

Derek Jones — Fri, 12 Jun 2009 07:51:57 +0000

I have received only positive feedback about Horizon Discovery, both from the academic and business community. There is great interest in Horizon’s technologies, and I am sure that with the team they have in place, they will make a great success of their opportunities. It is also worth noting that the Horizon team are also always willing to spend time talking with other early-stage ventures and other budding entrepreneurs sharing with them their experiences, and playing an active part in the biotech community.

Por: Dan Cowell

Dan Cowell — Thu, 11 Jun 2009 10:41:45 +0000

Having set up two companies in the biotech sphere and having firsthand experience using Horizon’s cell lines, there are two clear factors that make Horizon stand out: their business model and the quality of the science behind their technology.

It is rare that a company can deliver a new technology to market, be profitable and at the same time deliver value to all stakeholders involved. This has been achieved by dedication, belief, hard work and all without the injection of large amounts of venture capital. In addition, this business model has allowed Horizon to be successful while allowing academic groups to benefit from the commercialization strategy and retention of the control of the company by the founders. This is seldom achieved.

With regard to the science, new technologies are often hyped, but seldom deliver. Our experience has show that the technology works, can be used to identify selective agents conclusively and questions why large panels of genetically disparate cell lines are still used to try and identify and classify new chemical entities.

Dan Cowell
CEO Hypoxium